Raloxifene Hydrochloride en es it fr

Raloxifene Hydrochloride Brand names, Raloxifene Hydrochloride Analogs

Raloxifene Hydrochloride Brand Names Mixture

  • No information avaliable

Raloxifene Hydrochloride Chemical_Formula


Raloxifene Hydrochloride RX_link


Raloxifene Hydrochloride fda sheet

Raloxifene_Hydrochloride FDA

Raloxifene Hydrochloride msds (material safety sheet)

Raloxifene_Hydrochloride MSDS

Raloxifene Hydrochloride Synthesis Reference

C. D. Jones et al., J. Med. Cem. 27, 1057(1984)

Raloxifene Hydrochloride Molecular Weight

473.584 g/mol

Raloxifene Hydrochloride Melting Point


Raloxifene Hydrochloride H2O Solubility


Raloxifene Hydrochloride State


Raloxifene Hydrochloride LogP


Raloxifene Hydrochloride Dosage Forms


Raloxifene Hydrochloride Indication

For the prevention of osteoporosis in post-menopausal women

Raloxifene Hydrochloride Pharmacology

Raloxifene, a selective estrogen receptor modulator (SERM) of the benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects on bone and lipid metabolism, while antagonizing the effects of estrogen on mammary tissue. Raloxifene decreases bone resorption, increases bone mineral density (BMD) and decreases incidence of fractures. Raloxifene is used in the prevention of postmenopausal osteoporosis and breast cancer.

Raloxifene Hydrochloride Absorption

Approximately 60% of an oral dose is absorbed, but presystemic glucuronide conjugation is extensive. Absolute bioavailability of raloxifene is 2.0%

Raloxifene Hydrochloride side effects and Toxicity

No information avaliable

Raloxifene Hydrochloride Patient Information


For safe and effective use of EVISTA, the physician should inform patients about the following:

Patient Immobilization: EVISTA should be discontinued at least 72 hours prior to and during prolonged immobilization
(e.g., post-surgical recovery, prolonged bed rest), and patients should be advised to avoid prolonged restrictions of
movement during travel because of the increased risk of venous thromboembolic events.

Hot flashes or flushes: EVISTA is not effective in reducing hot flashes or flushes associated with estrogen deficiency.
In some asymptomatic patients, hot flashes may occur upon beginning EVISTA therapy.

Other Preventive Measures: Patients should be instructed to take supplemental calcium and vitamin D, if daily dietary
intake is inadequate. Weight-bearing exercise should be considered along with the modification of certain behavioral
factors, such as cigarette smoking, and/or alcohol consumption, if these factors exist.

Physicians should instruct their patients to read the patient package insert before starting therapy with EVISTA and to
re-read it each time the prescription is renewed.

Raloxifene Hydrochloride Organisms Affected

Humans and other mammals